🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Rivaroxaban (Xarelto, BAY-59 7939)

Found 30 matching trials

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

PHASE2

The purpose of this study is to estimate the risk of bleeding with rivaroxa...

Status

Completed

Location

Multiple Locations

Start Date

2015-04-20

Trial ID

NCT02293395

Treatments Being Tested

Acetylsalicylic acid Rivaroxaban Clopidogrel Ticagrelor

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

PHASE1

Researchers in this study wanted to compare the effect of the formulation (...

Status

Completed

Location

Sumida Hospital

Start Date

2019-01-24

Trial ID

NCT04511611

Treatments Being Tested

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

N/A

This study is planned to collect prospective data and evaluate the safety a...

Status

Completed

Location

Sunshine Hospital

Start Date

2019-10-03

Trial ID

NCT03887780

Treatments Being Tested

Rivaroxaban (Xarelto,Bay 59-7939)

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

PHASE3

This is a multicenter, randomized, double-blind, event-driven, superiority ...

Status

Completed

Location

Multiple Locations

Start Date

2014-03-05

Trial ID

NCT02064439

Treatments Being Tested

BAY 59-7939 BAY 59-7939 ASA

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

PHASE3

The purpose of this study is to evaluate whether rivaroxaban reduces the ri...

Status

Terminated

Location

University of Arizona

Start Date

2020-08-13

Trial ID

NCT04508023

Treatments Being Tested

Rivaroxaban Placebo Standard of Care (SOC)

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

PHASE2

This study was a randomized, parallel group, open label trial using warfari...

Status

Completed

Location

Multiple Locations

Start Date

2005-09

Trial ID

NCT00973323

Treatments Being Tested

Xarelto (Rivaroxaban, BAY59-7939)Xarelto (Rivaroxaban, BAY59-7939)Xarelto (Rivaroxaban, BAY59-7939)Warfarin

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

N/A

Researcher in this study want to compare the effectiveness of Rivaroxaban (...

Status

Completed

Location

Multiple facilities

Start Date

2020-07-31

Trial ID

NCT04444804

Treatments Being Tested

Rivaroxaban (Xarelto, BAY 59-7939)LMWH and Phenprocoumon

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

PHASE1

Researchers in this study wanted to compare the effect of the formulation (...

Status

Completed

Location

Sumida Hospital

Start Date

2019-01-21

Trial ID

NCT04511637

Treatments Being Tested

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

PHASE3

The purpose of this study is to assess if 10 mg BAY 59-7939, taken once dai...

Status

Completed

Location

Multiple Locations

Start Date

2006-02

Trial ID

NCT00329628

Treatments Being Tested

Rivaroxaban (BAY59-7939)Enoxaparin

Bioequivalence Study of Rivaroxaban

PHASE1

The objectives of this study are to establish the bioequivalence between ri...

Status

Completed

Location

Multiple Locations

Start Date

2014-01

Trial ID

NCT02537457

Treatments Being Tested

Rivaroxaban (BAY 59-7939)Rivaroxaban (Xarelto, BAY 59-7939)

Previous Next